Please login to the form below
Eli Lilly increases Chinese sales by 26 per cent
Eli Lilly says its has grown sales of its pharmaceutical products in China by 26 per cent, compared with sales over a year ago, with 16 per cent growth for the pharmaceutical industry in the region as a whole
US-based pharmaceutical company Eli Lilly has said it has grown sales of its pharmaceutical products in China by 26 per cent, compared with sales over a year ago, with 16 per cent growth for the pharmaceutical industry in the region as a whole.
The company added that it expected to become the tenth largest company in the global pharmaceutical market by 2010. China is expected to become the seventh largest pharmaceutical market in 2012 and the second largest in 2020.
Lilly says it will introduce five drugs to the Chinese market in 2007 and an additional fifteen drugs over the next five years. The company signed an agreement with Hutchison Whampao, a drug development unit owned by Li Ka-shing, for the development of western drugs for treating cancer and inflammation.
Share
Related Hub content
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- Europe’s cancer community publishes new report on transforming patient care
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- AbbVie trial backs chemo-free Imbruvica combo regimen
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- EU to revise pharmaceuticals law amid antibiotic shortages
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
